Skip to main content
. 2018 Dec 28;17(2):2303–2307. doi: 10.3892/ol.2018.9876

Figure 3.

Figure 3.

Immunohistochemical expression of Ki-67 in a patient-derived xenograft model of pancreatic cancer bone metastasis following AZD4547 treatment. *P<0.05. Error bars indicate the standard deviation. Ki-67, marker of proliferation; NS, saline; CAP, capecitabine; AZD, AZD4547.